• Individualized Care in the Era of Immuno-Oncology: Focus on Bladder and Renal Cancers

    Immune checkpoint inhibitors play a key role in medical management of select patients with urologic cancers. Using interactive case discussions, this session will focus on the rationale for targeting the immune checkpoint pathway in bladder and renal cancers; the role of biomarkers such as programmed death-ligand 1 (PD-L1) and tumor mutation burden (TMB) to guide the selection of appropriate first- and subsequent-line therapy; the use of immune-specific response criteria to monitor treatment response; and options for managing immune-related adverse events during treatment.

    1.50 hours

    CME 1.50 AMA PRA Category 1 Credit™

This website uses cookies to ensure you get the best experience on our website. For more information on the cookies we use, please reference our Privacy Policy.